,40,41 However, clinical trials investigating mesothelin-directed CAR T cells to treat pancreatic cancer have had limited clinical efficacy thus far42 or are currently ongoing (ClinicalTrials.gov: NCT03323944 and NCT04577326). This evidence concerns the gene MSLN and familial pancreatic carcinoma.